Elegant antibody nanoparticles override immunological tolerance of tumors

Scientists from the Shanghai Institute of Materia Medica (SIMM) of the Chinese Academy of Sciences have developed a tumor enzymatic microenvironment-activatable antibody nanoparticle for robust cancer immunotherapy.